KEY POINTS
- This retrospective single-center study evaluated 103 patients with p16-positive oropharyngeal squamous cell carcinoma receiving definitive chemoradiotherapy with weekly cisplatin 40 mg/m² at Townsville University Hospital, Australia, between 2015 and 2021. Median follow-up was 56 months; 75 patients (73%) lived in rural or remote areas, 38 (37%) had T3–T4 disease, and 90 (87%) had N2–N3 disease according to AJCC seventh edition staging.
- Radiotherapy was delivered predominantly using VMAT, with 93/103 patients (90.3%) receiving 70 Gy in 35 fractions and 7 (6.8%) receiving 69.96 Gy in 33 fractions. Three additional patients discontinued RT after receiving at least a biologically equivalent dose of 66 Gy in 2-Gy fractions. Cisplatin was scheduled weekly for six cycles, targeting a cumulative dose of 240 mg/m², with additional administration in week seven when clinically indicated.
- At five years, overall survival was 84% (95% CI 76–92%) and progression-free survival was 80% (95% CI 72–89%). Corresponding two-year outcomes were 94% OS and 90% PFS, while only 4/103 patients (4%) developed locoregional recurrence and 5/103 (5%) developed distant metastatic recurrence during follow-up.
- Among 57 patients classified as low risk according to Ang criteria, five-year OS was 86% and PFS was 87%, with no locoregional recurrences and a five-year distant failure rate of 6%. These outcomes are encouraging, but they do not demonstrate that weekly cisplatin is equivalent to three-weekly high-dose cisplatin because both regimens were not compared within this study.
- The 46 intermediate-risk patients experienced five-year OS of 81% and PFS of 71%, with locoregional and distant failure rates of 10% and 7%, respectively. Progression-free survival was significantly worse than in the low-risk group (71% vs 87%; p=0.04), while the overall survival difference was not statistically significant (p=0.36), suggesting that smoking history and nodal burden remain relevant prognostic factors.
- Patients with T4 or N3 disease (n=24) had substantially worse outcomes despite excellent observed locoregional control. Five-year OS and PFS were both 55%, while the estimated distant failure rate reached 31% without recorded locoregional recurrence. Compared with the remaining patients, T4/N3 disease was associated with worse OS (HR 4.36, 95% CI 1.61–11.8; p=0.0038), emphasizing the importance of distant progression in this higher-risk subgroup.
- The median cumulative cisplatin dose was 240 mg/m², and 83/103 patients (81%) received at least 200 mg/m². Five-year OS did not differ significantly between patients receiving ≥200 versus <200 mg/m² (86% vs 78%; p=0.76), although the lower-dose group was small. Treatment toxicity led to cisplatin dose reductions in 8%, delays in 13%, and early discontinuation in 30%, most commonly related to cytopenias, mucositis, renal dysfunction or infection.
CLINICAL TAKEAWAY
Weekly cisplatin at 40 mg/m² combined with definitive RT produced favorable long-term disease control in this real-world cohort of p16-positive oropharyngeal cancer, including patients living in remote regions. However, the absence of a high-dose cisplatin control arm and incomplete comparative toxicity assessment mean these findings support the feasibility of weekly treatment rather than proving equivalent efficacy or improved tolerability.